Johnson & Johnson (JNJ) are in a variety of current events, prominently legal issues involving its talc products. J&J has settled some of these cases, including agreements to pay $700m for deceiving customers and incurring judgements such as a $260m verdict in Oregon. They have also completed the acquisition of Proteologix, another biotechnology company, for $850m and are considering purchasing Shockwave Medical in a massive $13.1 billion deal, signalling their intent to expand within the biotech field. As for their financial standing, recent reports suggest they are trading 0.5% higher despite a market uptick. Their financial reports, including third-quarter earnings and 2024 first-quarter earnings, have been released. J&J are intent on innovation, being named both on Fortune's 2024 Most Innovative Companies list and 2024 World's Most Admired Company. In line with their vision of becoming a global healthcare company, they have unveiled their 2023 Health for Humanity Report and are creating digital health solutions, as well as pledging a €125M upgrade to their Italy plant. They further plan to reach health equity, with special attention to veterans and military families.
Johnson Johnson JNJ News Analytics from Thu, 14 Sep 2023 07:00:00 GMT to Sun, 23 Jun 2024 09:10:31 GMT - Rating 0 - Innovation 8 - Information 7 - Rumor 3
